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Abstract
Emerging studies implicate the signalling of the mammalian target of rapamycin (mTOR) in a
number of reproductive functions. To this date, there are no data regarding the expression of
mTOR signalling components in the human myometrium during pregnancy. We hypothesized that
mTOR-related genes might be differentially expressed in term or preterm labour as well as in
labour or non-labour myometria during pregnancy. Using quantitative RT-PCR we demonstrate
for first time that there is a significant downregulation of mTOR, DEPTOR, and Raptor in preterm
labouring myometria when compared to non-pregnant tissues taken from the same area (lower
segment). We used an immortalised myometrial cell line (ULTR) as an in vitro model to dissect
further mTOR signalling. In ULTR cells DEPTOR and Rictor had a cytoplasmic distribution,
whereas mTOR and Raptor were detected in the cytoplasm and the nucleus, indicative of
mTORC1 shuttling. Treatment with inflammatory cytokines caused only minor changes in gene
expression of these components, whereas progesterone caused significant down-regulation. We
performed a non-biased gene expression analysis of ULTR cells using Nimblegen human gene
expression microarray (n=3), and selected genes were validated by quantitative RT-PCR in
progesterone treated myometrial cells. Progesterone significantly down-regulated key components
of the mTOR pathway. We conclude that the human myometrium differentially expresses mTOR
signalling components and they can be regulated by progesterone.
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A number of recent studies implicates mammalian target of rapamycin (mTOR) signalling in
reproductive functions. mTOR is a highly conserved Ser/Thr protein kinase that can form
two distinct complexes termed mTORC1 and mTORC2 which can exert diverse but separate
biological effects. The mTORC1 complex is sensitive to rapamycin treatment and contains
the following components: mTOR, Raptor, GβL (mLST8), PRAS40 and DEPTOR
(DEPDC6, DEP-containing protein 6). This complex is capable of regulating translational
processes and cell proliferation by altering the phosphorylation levels of downstream
molecules such as p70 ribosomal S6 kinase 1 (S6K) and the eukaryotic initiation factor 4E-
BP1 [1–2]. The mTORC2 complex appears to be insensitive to rapamycin and contains:
mTOR, Rictor, mSIN1, Protor-1, GβL and DEPTOR. The functions of mTORC2 have not
been as extensively studied as those of mTORC1. mTORC2 functions as a regulator of ATP
kinases as it can phosphorylate Akt, protein kinase Cα and serum-and glucocorticoid-
induced protein kinase [3] and has been proposed to function upstream of Rho GTPases to
regulate the actin cytoskeleton [4].
At the placental level, mTOR signalling is a key mechanism linking maternal nutrient and
growth factor concentrations to amino acid transport [5–7]. In growth restricted placentas,
mTORC1 activity appears to be compromised as depicted by changes in the phosphorylation
levels of S6K [7]. In addition, mTOR mediates human trophoblast invasion through
regulation of matrix-remodelling enzymes and is associated with serine phosphorylation of
STAT3 [8]. Our laboratory has demonstrated that during the process of syncytialization of
cytotrophoblast (BeWo) cells, the expression of mTOR and 4EBP was down-regulated
compared to unstimulated cells at the mRNA level [9]. We have also provided evidence for
behavioural (i.e. emotional) influences on mTOR signalling at placental level as there was a
significant inverse correlation between mRNA levels of placental DEPTOR and self-
reported levels of stress in pregnant subjects [10].
The human myometrium undergoes differentiation in terms of cell number and size in two
distinct stages of pregnancy: hyperplasia and hypertrophy [12]. The early phase of smooth
muscle cell (SMC) proliferation (hyperplasia) which precedes implantation then gives rise to
an intermediate synthetic phase [12]. During gestation the myometrium undergoes mainly
hypertrophy, a phase of increased production of extracellular matrix proteins and subsequent
increase of SMC size. The exact mechanisms that cause this particular switch from one
phenotype to the other have not been fully elucidated. Shynlova et al., have demonstrated in
a rodent model that the synthetic phase coincides with changes in the expression of certain
caspases, as well as PARP [12].
mTOR has been implicated in the reconditioning of the myometrium during early stages of
gestation in rodents. Jaffer et al., have provided conclusive evidence using an in vivo rat
model that estradiol (E2) can induce the PI3K/mTOR signalling pathway in the
myometrium, leading to uterine smooth muscle proliferation [11]. This study implicates
mTOR signalling in events leading to the induction of myometrial hyperplasia during early
gestation in a rodent model.
In contrast, to the best of our knowledge there are no reports on the expression of key
mTOR signalling components in the human myometrium and in pathologies such as preterm
labour. Preterm labour is defined as labour that begins before 37 completed weeks of
pregnancy and is still the leading cause of perinatal morbidity and mortality in the developed
world [13]. Despite advances in the diagnosis and molecular basis of this disease, efforts to
prevent preterm birth have been compromised by a poor understanding of the underlying
pathophysiology and not fully effective therapeutic interventions. However, we do know
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that preterm labour is associated with an inflammatory response and subsequently higher
circulating levels of cytokines such as IL-1β, IL-6, IL-8 and TNFα *14+. Interestingly,
progesterone (P4) can exert anti-inflammatory effects in the context of intrauterine infection
and also modulates myometrial contractile tone [15]. Previous studies have shown that the
P4 plays a major anti-inflammatory role in human myometrial cells by antagonism of NF-
κB activation of COX2 expression [16]. More recently, we have also shown that P4 inhibits
the effects of IL-1β in two placental cytotrophoblast cell lines *17+. We hypothesized that
myometrial mTOR signalling might be altered in different stages (term or preterm) and
contractile status (labour or non-labour) during pregnancy. We investigated this hypothesis
by mapping the expression of mTOR, Rictor, Raptor and DEPTOR in clinical samples and
assessing the effects of inflammatory cytokines and progesterone on the expression of these
components as well as the activity of mTORC1 and mTORC2 complexes.
Materials and Methods
Subjects
The study population consisted of pregnant women attending the Department of Obstetrics
and Gynaecology, University Hospital, University of Crete. All participants gave informed
consent to participate in the study and ethical approval was granted by the local ethics
committee of the hospital as well as Brunel University. Women who were delivered by
elective caesarean section at term and showed no signs of labour (uterine contractions and/
or cervical changes) formed the non-labouring group (n=3). Women who entered
spontaneous and established labour (at least 2 h) but required emergency caesarean section
formed the labouring group (n=17). Clinical indications for emergency caesarean section
included breech (1), fetal distress (5), prolonged labour and failure to progress in labour (7)
and previous caesarean section (4). A labour is defined as prolonged when its duration
exceeds 18 to 24 hours for nulliparous and 14 hours in multiparous.
Similarly we have obtained clinical samples for preterm labour (n=6) and preterm non
labour (n=5). Clinical indications for CS in the preterm non-labour group were preterm
premature rupture of membranes (PPROM) and chorioamnionitis, tranverse lie with cord
prolapse after PPROM, and unprovoked fetal distress. The non pregnant samples (n=18)
were obtained from premenopausal women undergoing hysterectomy for non malignant
conditions. Myometrial tissue samples (both pregnant and non pregnant) were collected
from the lower uterine segment, immediately snap frozen in liquid nitrogen and stored at
−80° C for subsequent mRNA analysis. Ethical approval has been obtained by the local
ethics committee.
Cell culture
ULTR cells were a kind gift from Dr Xiaolan Cui (Department of Obstetrics and
Gynecology, University of Cincinnati, USA). The cells were maintained at standard culture
conditions of 5% CO2 in air at 37° C. ULTR cells were cultured in DMEM + Glutamax-1
(Fisher, UK) containing 10% heat-inactivated fetal bovine serum (FBS), and 0.5%
penicillin-streptomycin.
RNA isolation and cDNA synthesis for qRT-PCR
Total ribonucleic acid was isolated using an RNA extraction kit (Sigma), according to the
manufacturer’s instructions. RNA concentration was determined by spectrophotometric
analysis (NanoDrop; Thermo Scientific). RNA (200ng from placental tissue and 500 ng
from cell lysates) was reverse-transcribed into cDNA using 5 IU/μl Superscript II reverse
transcriptase (Invitrogen).
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Relative expression of the genes of interest was assessed by quantitative RT-PCR (qRT-
PCR) on an ABI7900 instrument (Applied Biosystems) using SYBR® Green-PCR reaction
mixture (Sigma-Aldrich, UK) and the primers as previously described [18]. As a negative
control for all the reactions, distilled water was used in place of the cDNA. RNAs were
assayed from two to three independent biological replicates. The RNA levels were expressed
as a relative quantification (RQ) value, using Delta Ct method for comparing relative
expression results between treatments in qRT-PCR using primers as previously described
[18].
Immunofluorescent analysis
ULTR cells were fixed in 4% paraformaldehyde for 10 min prior to washes in PBS and
incubation with 10% bovine serum albumin (BSA) for 1 hr. Cells were incubated for 1 hr
with antibodies against mTOR, DEPTOR, Rictor and Raptor (Cell Signalling, USA) at a
1:200 dilution in 1% BSA/PBS. Cells were then washed with PBS prior to an incubation
with anti-rabbit IgG-fluorescein isothiocyanate (FITC)-conjugated antibody (Santa Cruz
Biotechnology, USA) for 1 hr. Slides were washed with PBS and mounted in Vectashield®
Mounting Medium (Vector labs) containing the dye 4,6-diamido-2-phenylindole (DAPI) to
counterstain nuclei. Images were captured using a Plan Apo Neofluor 63X NA 1.25 oil
objective (Zeiss) on a Zeiss Axiovert 200M microscope and viewed using AxioVision
software.
Nimblegen Microarray
ULTR cells were treated with 30 nM P4 for 24 hrs and RNA was obtained using an RNA
extraction kit (Sigma), according to the manufacturer’s instructions. The RNA was purified
and DNase treated using the RNAeasy (Qiagen) clean up protocol supplied by the
manufacturer. cDNA was created from 100 ng RNA using the Transplex complete whole
transcriptome amplification kit (Sigma). The cDNA sample was RNase (Sigma) treated and
cDNA precipitated using the protocol supplied with the Nimblegen Expression Array
(Roche). Samples were labelled with Nimblegen labelling kit using Cy3 and hybridised to a
Nimblegen 12plex × 135k gene Human transcriptome microarray and washed to according
to the supplier’s protocol. The Nimblegen array slide was scanned at 3μm on an InnoScan
700 Microarray Scanner for TIFF images using Mapix v. 5.1 software. The TIFF images
were aligned to their Nimblegen design files and converted into probe intensity values using
the Nimblegen DEVA software. The Data was normalised across the array using RMA
methods in DEVA. This was imported into DNAstar (ArrayStar Inc.). Pathway analysis was
carried out by inputting mTOR-elated genes with ±20% changes into DAVID v. 6.7 (http://
david.abcc.ncifcrf.gov).
Statistical analysis
Statistical analysis of the ΔCt values was performed by one-way analysis of variance
(ANOVA), followed by Bonferroni Multiple Comparison as a post hoc test using GraphPad
Prism 5.0.
Results
Expression of mTOR, DEPTOR, Rictor, Raptor in human myometrium
qRT-PCR analyses demonstrated that mTOR was only significantly down-regulated in
preterm-labour compared to non pregnant status (Figure 1A). DEPTOR is significantly
down-regulated in all the different categories of pregnant myometria when compared to non
pregnant myometrium (Figure 1B). In the pregnant myometrium, DEPTOR was up-
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regulated at term non-labour and down-regulated in preterm labour when compared to term-
labour (Figure 1B). Rictor showed the least differences in gene expression and there were no
apparent differences in its expression across all different groups (Figure 1C). Raptor was
significantly up-regulated at term non-labour and down-regulated at preterm labour
compared to the non-pregnant group (Figure 1D).
Effects of inflammatory cytokines on mTOR, DEPTOR, Rictor, Raptor in ULTR cells
Following the mapping of these components in clinical samples, we evaluated the ULTR
human myometrial cell line as an in vitro model to further study mTOR signalling. RT-PCR
analyses confirmed that all key components are expressed at the mRNA level (Figure 2A).
Immunofluorescent analysis was then performed to elucidate protein expression and cellular
distribution of these genes. All components appeared to have a strong cytoplasmic
distribution with mTOR and Raptor also demonstrating some nuclear staining (Figure 2B).
ULTRs were treated for 24 hrs with IL-1β, IL-6, IL-8 and TNF-α (1ng/mL) individually and
together as a cytokine mix in attempt to mimic an inflammatory milieu in vitro. Most of the
cytokines did not alter gene expression (Fig 3). Treatment with TNF-α significantly down-
regulated DEPTOR but not mTOR, Raptor or Rictor when compared to basal (unstimulated)
levels (Figure 3B). Similarly, incubation of myometrial cells with a mix of all the cytokines
did not induce any significant changes in the expression of these genes when compared to
control (Figure 3 A–D).
Effects of progesterone (P4) on mTOR signalling components: validation of microarray
data
We performed a gene expression analysis using the NimbleGen chip array in ULTRs treated
with 30nM P4 for 24 hrs. By analyzing three pairs of independent replicates of P4 treated
against unstimulated controls, 1644 significantly differentially expressed genes were
identified. We concentrated on the potential effects P4 can exert on the mTOR pathway
(Figure 4). The following genes had lower transcript abundance compared to basal levels:
DEPTOR (72%), GβL (30–50%), Rictor (29%), Raptor (18%), Akt1 (37–60%), RHEB
(17%), TSC2 (38%), PRAS40 (17–53%), IRS1 (40%), REDD1 (18%), LKB1 (22%),
STRAD (45%), MO25 (27%), HIF1α (21–29%), VEGF (14–39%), and AMPK (18%). Of
those only GβL, Rictor, and TSC2 appeared to be downregulated significantly (p≤0.05). On
the contrary upregulation following P4 treatment of PKCα (50%), PDK1 (52–63%), TSC1
(25–90%), S6K1 (4–23%), ERK1 (66%), and ERK2 (22–71%) was observed.
The qRT-PCR results for the genes in the mTOR pathway (mTOR, DEPTOR, Rictor,
Raptor) in an independent validation set were consistent with the results from the microarray
data analysis. Treatment of cells with P4 (30nM) caused significant down-regulation of
mTOR (65%), DEPTOR (50%), Rictor (57%), and Raptor (70%) when compared with basal
levels (Figure 3E).
Discussion
This study provides the first evidence for differential expression of key signalling
components of the mTOR pathway in the human myometrium during pregnancy. In
addition, this study is the first to identify and validate the patterns of gene expression
associated with myometrial mTOR signalling in P4-treated cells.
Immunofluorescent analysis revealed strong cytoplasmic staining for DEPTOR and Rictor,
whereas mTOR and Raptor had cytoplasmic as well as nuclear distribution. These data
corroborate our previous findings where a cytosolic expression of mTOR in BeWo and
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JEG-3 cytotrophoblast cell lines [9] and in two ovarian cancer cell lines (SKOV-3 and
PEO1) [18] was noted. Other studies have also shown cytoplasmic localisation of mTOR [7,
19], although it has been argued that mTOR can also shuttle between the nucleus and
cytoplasm, an event necessary for the maximal activation of S6K1 [20]. It has been
proposed that mTORC1 complex is predominantly cytoplasmic whereas the mTORC2
complex is abundant in both compartments [21].
One of the main findings is the significant down-regulation of DEPTOR in all pregnant
states when compared to non pregnant controls. DEPTOR binds to both mTORC1 and
mTORC2 and knocking down DEPTOR leads to activation of signalling through both
complexes [22]. Therefore, we also represented the qRT-PCR data as a ratio of mTOR/
DEPTOR. The ratio of mTOR to DEPTOR was decreased in non-labour irrespective of
whether the myometrium was at term (from 2.8 to 1.6) or preterm when compared with the
labouring samples (from 3.8 to 2.3). Indeed mTORC1 has been shown to be involved with
control of cellular proliferation in numerous in vitro as well as in vivo models. For example,
there is an increase in the phosphorylation of mTOR and S6K1 during the proliferative
phase in the rat myometrium, and treatment of myometrial cells with rapamycin
significantly reduced cell proliferation [11]. Our studies tend to corroborate the clinical
significance, since the dramatic down-regulation during pregnancy of DEPTOR would allow
changes of the myometrial phenotype as activation of the mTORC1 complex can allow
progression of myometrium from the proliferative to the synthetic stage.
It has been shown that there is significant and widespread thinning of the myometrium
during active labour and that descent of the fetal head during the second stage of labour is
associated with a significant relative thickening of the anterior and fundal myometrium [23].
The authors of the study proposed a model where “the myometrium grows symmetrically
during pregnancy and thins significantly at all sites during active labour including the
fundus”. Moreover, it has been proposed that the myometrium might also harbour stem/
progenitor cells that can play a key role in uterine remodelling [24–25]. Of interest, mTOR
can regulate smooth muscle differentiation from progenitor cells [26]. During pregnancy, the
wet weight of the uterus increases 10-fold largely due to myometrial smooth muscle cell
hypertrophy and hyperplasia. It is attractive to speculate that the down-regulation of the
mTOR/DEPTOR ratio in all non-labouring myometrial might compromise the activity of
mTORC1 complex thus preventing a full reconstruction of the uterine cavity during
pregnancy that can affect the contractile phenotype towards the end. Interestingly, in a study
of twin pregnancies, in the absence of uterine contractions or symptoms of preterm labour,
twins that delivered preterm had a significantly thinner lower uterine segment at an earlier
gestation, compared with twins that delivered at term; suggesting that lower uterine segment
thinning occurred earlier in these cases [27].
There is increasing evidence that mTOR signalling is under the influence of steroids. In the
myometrium of ovariectomized rats, E2 activated the mTOR signalling pathway [11],
whereas we have shown that cortisol-treatment of cytotrophoblast cells down-regulated
DEPTOR [10]. Moreover, P4 suppressed mTOR pathway in induced regulatory T cells
[iTreg, 28]. iTreg cells were prepared by 5-day activation of naive T cells with concanavalin
A and interleukin-2 [28]. However, E2+P4 induced mammary tumour growth in rats via
activation of mTOR signalling and phosphorylation of S6K and 4EBP1 [29]. In
ovariectomized mice, P4 treatment significantly increased levels of S6K in the dorsal
hippocampus [30]. In an attempt to dissect further the effects of P4 on ULTR cells, we
performed an mTOR-related gene expression analysis using NimbleGen microarray. We
noted down-regulation of a number of transcripts within the mTORC1 and mTORC2
complexes, as well as upstream and downstream effectors in P4 treated samples. We have
confirmed these findings using qRT-PCR. Our study follows previous microarray-based
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work, where it was shown that mTOR is one of the most highly up-regulated pathways in
leiomyomata [31].
Taken together, the results suggest that in addition to other pleiotropic effects of P4 at the
uterine level, this sex steroid also modulates mTOR signalling which has potential clinical
significance. We therefore propose the following model: Early in pregnancy when the P4
levels are low mTOR signalling components are unaffected. As a result, an intact mTOR
signalling system favours a state of myometrial hyperplasia. Later on, the rise in P4 levels
will antagonize the proliferative effects of E2 and downregulate mTOR signalling. This
promotes a state of hypertrophy where there is an increase in the cell size but not in the cell
number. At the end of pregnancy “functional” progesterone withdrawal will shift the
myometrium from a quiescent state to a contractile one initiating labour.
One of the limitations of this study is that due to ethical restrictions, we could only obtain
samples from the lower segment and not from the fundus. However, it has been clearly
demonstrated that the increased expression of IL-8, PGHS-2, IL-1β and CX-43, i.e. genes
associated with labour is greatest in the lower segment [32]. Collectively, the changes in
these key genes occurring in the lower uterine segment appear to drive the overall process
during labour and subsequently inducing the fundal contractile activity [32].
Future studies should determine the cellular localisation of mTORC1 and mTORC2
complexes in human myometria, especially in tissues from complicated pregnancies such as
preterm labour, in order to define whether mTOR shuttling might affect subsequent
signalling in certain pathologies. Moreover, future work should elucidate whether P4 can
also affect the phosphorylation status of mTOR, S6K, 4EBP, Akt, PKCα and whether it can
also affect trafficking of mTOR in myometrial cells.
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• DEPTOR was in all pregnant states when compared to non-pregnant myometria.
• The human myometrial ULTR cell line express mTORC1 and mTORC2
components.
• Progesterone down-regulated mTOR, DEPTOR, Rictor and Raptor in
myometrial cells.
• Microarray revealed down-regulation of mTOR-related signalling components
in P4-treated samples.
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Figure 1. Differential regulation of mTOR-related components in human myometria: down-
regulation of DEPTOR in all pregnant states when compared to non-pregnant controls
Quantitative analyses of mTOR (A), DEPTOR (B), Rictor (C), and Raptor (D) mRNA in
human myometria. NP: non pregnant, TL: term labour, T-NL: term no labour, PT-L: preterm
labour, PT-NL: preterm no labour. * p<0.05 compared to NP levels for mTOR and Raptor,
†p<0.05 compared to NP for DEPTOR and * p<0.05 for DEPTOR compared to TL samples.
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Figure 2. The ULTR myometrial cell line expresses mTOR, DEPTOR, Rictor and Raptor at
mRNA and protein level
Immunofluorescent analysis indicates a strong cytoplasmic distribution with mTOR and
Raptor. Expression and cellular distribution of mTOR components in ULTR cells. Panel A:
Lane 1 DNA marker, Lane 2 cDNA from BeWo cells (positive control), lane 3: cDNA from
ULTR cells, and lane 4: negative control RT−). Panel B: Representative images showing
cellular distribution of mTOR, DEPTOR, Rictor and Raptor in ULTR cells using
immunofluorescent analysis. Magnification x40
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Figure 3. Progesterone but not IL-1β, IL-6, IL-8 down-regulated mTOR, DEPTOR, Rictor and
Raptor, compared to unstimulated control cells
Myometrial cells were treated with for 24 hrs with IL-1β, IL-6, IL-8 and TNF-α (1ng/mL)
and levels of mTOR (A), DEPTOR (B), Rictor (C) and Raptor (D) were assessed. Only
TNF-α significantly (*p<0.05) downregulated DEPTOR’s expression. Panel E: Cells were
treated with 30nM P4 for 24 hrs and the levels of mTOR, DEPTOR, Rictor, and Raptor were
assessed compared to basal levels that were set up as 1.0 in terms of RQ value (*p<0.05
compared to basal levels).
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Figure 4. NimbleGen microarray revealed down-regulation of a number of mTOR-related
transcripts, as well as upstream and downstream effectors in P4-treated samples
Functional annotation table of the components related to the mTOR pathway that have been
downregulated (red rectangle) and upregulated (blue rectangle) following P4 treatment
based on Nimblegen array data.
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